^
    Back
    Association details:
    Biomarker:Chr inv(16)(p13;q22)/ CBFB-MYH11 fusion
    Cancer:Acute Myelogenous Leukemia
    Drug:cytarabine (DNA synthesis inhibitor, DNA-directed DNAP inhibitor) +
    daunorubicin (Topoisomerase II inhibitor, DNA intercalator)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Cancer Genet Cytogenet
    Title:

    Truncated RUNX1 Generated by the Fusion of RUNX1 to Antisense GRIK2 via a Cryptic Chromosome Translocation Enhances Sensitivity to Granulocyte Colony-Stimulating Factor

    Published date:
    06/16/2020
    Excerpt:
    Here, we describe a 59-year-old male patient who was initially diagnosed with acute myeloid leukemia, inv(16)(p13;q22)/CBFB-MYH11 (FAB classification M4Eo). He achieved complete remission and negative CBFB-MYH11 status with daunorubicin/cytarabine combination chemotherapy but relapsed 3 years later.
    DOI:
    10.1159/000508012